Liquid biopsies in lung cancer: The new ambrosia of researchers

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 539-546

  Rolfo, Christian ^a   Castiglia, Marta ^a,b   Hong, David ^c   Alessandro, Riccardo ^d   Mertens, Inge ^e,f   Baggerman, Geert ^e,f   Zwaenepoel, Karen ^a   Gil Bazo, Ignacio ^g   Passiglia, Francesco ^a,b   Carreca, Anna P ^a   Taverna, Simona ^d   Vento, Renza ^d   Peeters, Marc ^a   Russo, Antonio ^b   Pauwels, Patrick ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PALERMO   (Italy)

^e FLEMISH INSTITUTE FOR TECHNOLOGICAL RESEARCH VITO   (Belgium)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Biomarkers; Circulating tumor cells; Circulating tumor DNA; Exosomes; Lung cancer

Indexed keywords

CIRCULATING TUMOR DNA; DNA; MICRORNA; UNCLASSIFIED DRUG; TUMOR MARKER;

APOPTOSIS; BIOPSY; BLOOD SAMPLING; BODY FLUID; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ASSAY; CELL COUNT; CELL ISOLATION; CELL MIGRATION; CELL SIZE; CIRCULATING TUMOR CELL; DISEASE MARKER; DNA DETERMINATION; DNA SEQUENCE; EGFR MUTATION; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; GENE EXPRESSION PROFILING; HUMAN; LIQUID BIOPSY; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; ONCOGENE; OVERALL SURVIVAL; PATIENT MONITORING; PREDICTIVE VALUE; PROTEIN SECRETION; REVIEW; SECRETOME; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BLOOD; LUNG TUMOR; PATHOLOGY; TUMOR EMBOLISM;

ANIMALS; BIOPSY; DNA, NEOPLASM; EXOSOMES; HUMANS; LUNG NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 84908343167     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.10.001     Document Type: Review

References (84)

1. Alix-Panabieres C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59(1):110-118.
2. Dawson S.J., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368(13):1199-1209.
3. Murtaza M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497(7447):108-112.
4. Welton J.L., et al. Proteomics analysis of bladder cancer exosomes. Mol. Cell. Proteomics 2010, 9(6):1324-1338.
5. Chan K.C., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 2013, 59(1):211-224.
6. Allard W.J., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10(20):6897-6904.
7. Krebs M.G., et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 2011, 29(12):1556-1563.
8. Hiltermann T.J., et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 2012, 23(11):2937-2942.
9. Chen X., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18(10):997-1006.
10. Weber D.G., et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res. Notes 2013, 6:518.
11. Leon S.A., et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37(3):646-650.
12. Wolfers J., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001, 7(3):297-303.
13. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2(8):569-579.
14. Rodriguez M., et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosom. Cancer 2014, 53(9):713-724.
15. Valadi H., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9(6):654-659.
16. Blanc L., et al. Exosome release by reticulocytes-an integral part of the red blood cell differentiation system. Blood Cells Mol. Dis. 2005, 35(1):21-26.
17. Corrado C., et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int. J. Mol. Sci. 2013, 14(3):5338-5366.
18. Pantel K., Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 2013, 73(21):6384-6388.
19. Thakur B.K., et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014, 24(6):766-769.
20. Pavlou M.P., Diamandis E.P. The cancer cell secretome: a good source for discovering biomarkers?. J. Proteome 2010, 73(10):1896-1906.
21. Polisetty R.V., et al. Glioblastoma cell secretome: analysis of three glioblastoma cell lines reveal 148 non-redundant proteins. J. Proteome 2011, 74(10):1918-1925.
22. Torti D., Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 2011, 3(11):623-636.
23. Bronte G., et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev. 2010, 36(Suppl. 3):S21-S29.
24. Soda M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
25. Rolfo C., et al. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?. Expert Opin. Ther. Targets 2014, 18(9):983-985.
26. Bronte G., et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit. Rev. Oncol. Hematol. 2014, 89(2):300-313.
27. Steuer C.E., Ramalingam S.S. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer 2014, 120(16):2392-2402.
28. Rolfo C., et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat. Rev. 2014, 40(8):990-1004.
29. Taniguchi K., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 2011, 17(24):7808-7815.
30. Oxnard G.R., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20(6):1698-1705.
31. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med. J. Aust. 1869, 14:146-147.
32. Gallivan M.V., Lokich J.J. Carcinocythemia (carcinoma cell leukemia). Report of two cases with English literature review. Cancer 1984, 53(5):1100-1102.
33. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2(6):442-454.
34. Steeg P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer 2003, 3(1):55-63.
35. Maheswaran S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359(4):366-377.
36. Costa D.B. Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer?. J. Clin. Oncol. 2013, 31(18):2236-2239.
37. Huang J., et al. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PLoS One 2013, 8(11):e78070.
38. Igawa S., et al. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol. Lett. 2014, 7(5):1469-1473.
39. Normanno N., et al. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer 2014, 85(2):314-319.
40. Hayes D.F., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006, 12(14 Pt 1):4218-4224.
41. Danila D.C., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 2007, 13(23):7053-7058.
42. Cohen S.J., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26(19):3213-3221.
43. Wu C., et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J. Thorac. Oncol. 2009, 4(1):30-36.
44. Nagrath S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450(7173):1235-1239.
45. John T., Liu G., Tsao M.S. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl. 1):S14-S23.
46. Marchetti A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 2005, 23(4):857-865.
47. Stroun M., et al. The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci. 2000, 906:161-168.
48. Aung K.L., et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J. 2010, 4(1-4):11-21.
49. Utting M., et al. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin. Cancer Res. 2002, 8(1):35-40.
50. Jahr S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61(4):1659-1665.
51. Giacona M.B., et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998, 17(1):89-97.
52. Zhong X.Y., et al. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch. Gynecol. Obstet. 2007, 276(4):327-331.
53. Sozzi G., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 2003, 21(21):3902-3908.
54. Chen X., et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin. Cancer Res. 1999, 5(9):2297-2303.
55. Nygaard A.D., et al. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br. J. Cancer 2014, 110(2):363-368.
56. Nygaard A.D., et al. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer 2013, 79(3):312-317.
57. Benesova L., et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal. Biochem. 2013, 433(2):227-234.
58. van der Vaart M., Pretorius P.J. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?. Clin. Biochem. 2010, 43(1-2):26-36.
59. Umetani N., et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 2006, 52(6):1062-1069.
60. Sriram K.B., et al. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer 2012, 12:428.
61. Zane M., et al. Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): a non-invasive tool panel for early detection of thyroid cancer. Biomed. Pharmacother. 2013, 67(8):723-730.
62. Taylor D.D., Doellgast G.J. Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal. Biochem. 1979, 98(1):53-59.
63. Taylor D.D., Homesley H.D., Doellgast G.J. Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments. Cancer Res. 1980, 40(11):4064-4069.
64. Zhang H.G., Grizzle W.E. Exosomes and cancer: a newly described pathway of immune suppression. Clin. Cancer Res. 2011, 17(5):959-964.
65. Kahlert C., Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. (Berl.) 2013, 91(4):431-437.
66. Ratajczak J., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20(5):847-856.
67. Yanaihara N., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9(3):189-198.
68. Rabinowits G., et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10(1):42-46.
69. Rana S., Malinowska K., Zoller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013, 15(3):281-295.
70. Wei F., Yang J., Wong D.T. Detection of exosomal biomarker by electric field-induced release and measurement (EFIRM). Biosens. Bioelectron. 2013, 44:115-121.
71. Chen C., et al. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 2010, 10(4):505-511.
72. Mathivanan S., et al. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2012, 40(Database issue):D1241-D1244.
73. Thery C., et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006, Chapter 3: p. Unit 3 22. Suppl. 30: p. 3.22.1-3.22.29.
74. Crescitelli R., et al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J. Extracell. Vesicles 2013, 2.
75. Webber J., Clayton A. How pure are your vesicles?. J. Extracell. Vesicles 2013, 2.
76. Lasser C., Eldh M., Lotvall J. Isolation and characterization of RNA-containing exosomes. J. Vis. Exp. 2012, (59):e3037.
77. Fontana S., et al. Contribution of proteomics to understanding the role of tumor-derived exosomes in cancer progression: state of the art and new perspectives. Proteomics 2013, 13(10-11):1581-1594.
78. Park J.O., et al. Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics 2013, 13(14):2125-2134.
79. Tjalsma H., et al. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol. Mol. Biol. Rev. 2000, 64(3):515-547.
80. Volmer M.W., et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5(10):2587-2601.
81. Gronborg M., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5(1):157-171.
82. Yu C.J., et al. Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J. Proteome Res. 2011, 10(10):4671-4682.
83. Xiao T., et al. An approach to studying lung cancer-related proteins in human blood. Mol. Cell. Proteomics 2005, 4(10):1480-1486.
84. Chen Y., et al. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer 2006, 54(1):95-102.